A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 801–831 of 831
Lin, H.-Y., Tseng, H.-Y., Lin, C.-C., Tzeng, W., Hou, T.-Y., Li, W. C., Lin, Y., Yin, S., Wang, C.-C., Liu, Y.-Y., et al. (2026) · Genes · doi:10.3390/genes17080860
“A protein-truncating variant (rs72613567: TA) in HSD17B13 has been linked to a reduced risk of NASH and fibrosis [11–13], with similar protective effects noted in hepatocarcinogenesis and alcoholic liver disease [14,15].”
Self-citationMetabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine
Lonardo, A., & Weiskirchen, R. (2026) · Metabolites · doi:10.3390/metabo16080529
“By contrast, loss-of-function variation in HSD17B13 attenuates liver injury and protects against chronic liver disease progression without necessarily preventing steatosis, highlighting the importance of downstream injury-resolution pathways as therapeutic targets [101–103].”
Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere
Hugelshofer, C. L., Stateman, L. M., Shockley, S. E., Augustin, M. A., Bandera, A. M., Bee, C., Choy, J. W., Chrencik, J., Ellsworth, K. P., Fincher, J. A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01224
Jones, E., Eppler, N., Ahamed, F., & Zhang, Y. (2026) · Livers · doi:10.3390/livers6040074 · Cited by 3
“In contrast, the loss-of-function hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567 T>A variant is associated with reduced susceptibility to ALD and HCC [151].”
Tsai, S. Y., Uwera, G. B., Roehm, B. A., Pandey, A., & VanWagner, L. B. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001209
Guariglia, M., Caviglia, G. P., Gaia, S., Rosso, C., Rolle, E., Saba, F., Dileo, E., Silvestri, G. M., Armandi, A., CARUCCI, P., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1931260
“The lack of association between OS and the other established MASLD-related risk variants, including PNPLA3 , TM6SF2 , GCKR , and HSD17B13 , may re fl ect the distinction between genetic determinants of MASLD/HCC susceptibility and genetic modi fi ers of outcome after HCC diagnosis (6, 7).”
Vishnubhotla, R., Govardhan, B., Kulkarni, A. V., Reddy, D. N., & Rao, P. N. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103636
Slabber, C. F., Lenkeit, F., Grove, K. J., Aebi, A., Orsini, V., Reyes, A., Ludwig, V., Crochemore, C., Bergling, S., Wild, S. A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106429
“11,36,37 It remains to be determined how the different features of HSD17B13 variants, such as zonation, expression levels, and enzymatic activity, individually contribute to protection against fibrotic liver disease progression.”
Meng, Q., Wang, X., Zhang, Y., Pushpakom, S. P., Yang, J., Feng, H., & Wang, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354751
“The 17 β -hydroxysteroid dehydrogenase 13 (HSD17B13) gene has emerged as a promising therapeutic target [7].”
Theocharidou, E., Arvanitakis, K., Koufakis, T., Tsochatzis, E. A., Francque, S., & Germanidis, G. S. (2026) · Drugs · doi:10.1007/s40265-026-02362-6 · Cited by 1
“In contrast, the variants associated with hepatic lipid retention (PNPLA3, TM6SF2) are associated with a higher risk of advanced liver disease, but they decrease or have no effect on CVD risk [125].”
InfluentialSuresh, K. B., Bhatia, R., Sajawal, M., Sabet, O., Zahedi, I., Rameau, A., Fadaka, A., Bajwa, W., Shahid, M. B., Alvi, S., et al. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102909
Kumar, S., Aceves, M., Guerra, L., Granados, J., Novilla, E., Juarez, F., Oluwadairo, T., Leandro, A. C., Leandro, M., Peralta, J. M., et al. (2026) · Cells · doi:10.3390/cells15171592
Lei, S., Tao, J., Chen, X., Li, X., & Zhong, S. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-03055-5
“Protein-truncating variants in hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) are associated with a lower risk of chronic liver disease, and hepatic Hsd17b13 knockdown attenuates high-fat diet (HFD)-induced steatosis and liver injury [29, 30].”
Cinque, F., Meroni, M., Badiali, S., Longo, M., Paolini, E., Galfrascoli, E., Oberti, G., Pisano, G., Maffi, G., Mureddu, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71345
Akanbi, A., Bridle, K. R., & Crawford, D. H. (2026) · Bioscience Reports · doi:10.1042/bsr20250106
“Additional findings have revealed that a loss-of-function variant in HSD17B13 is associated with a reduced risk of chronic liver disease and progression from steatosis to steatohepatitis [41], while impaired TM6SF2 function causally contributes to liver disease progression [42].”
Guo, Y., & Yao, Q. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102817
“…target knockdown must translate into benefit beyond approved treatments [18,43 – 45]. siRNA may provide added value by suppressing genetically or causally supported intracellular hepatic targets that are not readily addressed by current drugs, particularly PNPLA3 and HSD17B13 [14 – 16 , 55 ].”
Gawrieh, S., Tan, J., Guo, X., Schwantes-An, T.-H. L., Abreu, M., Zaborenko, C. J., Gómez, E. V., Schwimmer, J. B., Rotter, J. I., & Chalasani, N. (2026) · Liver International · doi:10.1111/liv.70907
Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis
Chalasani, N., Taub, R. A., Mogg, R., Labriola, D., Camacho, R. C., Zhang, H., & Anstee, Q. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.037
Krawczyk, M. J., Grünhage, F., Schubert, L., Dikopoulos, N., Schwenzer, J., Muche, M., Wiegand, J., Felten, G., Heyne, R., Ingiliz, P., et al. (2026) · United European Gastroenterology Journal · doi:10.1002/ueg2.70298
“It was first detected by Abul‐Husn et al., who showed its potentially protective effects in patients with chronic liver diseases [16].”
Yu, F., Yin, S., Jiayu, Z., & Sun, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1969017
“Risk variants in genes such as PNPLA3 (126), TM6SF2 (127), membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) (128), and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) (129) can significantly accelerate progression from simple steatosis to MASH and fibrosis by influencing lipid droplet metabolism, infla…”
Omaima, H. A. A. A., Saihood, S. S., Burhan, A. H., Aboomaima, W. A. A., Rostami, M., Raoufinia, R., & Mahmoudi, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.122892
Insulin resistance and hepatic steatosis
Tomović, A., Bakovic, N., Pantić, I., Baljosevic, N., Ranković, I., & Alempijevic, T. M. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102150
Qin, Z., Juramt, D., Chen, Y., Li, Y., Wei, J., Yang, H., Chen, L., & Qiu, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1946657
“By contrast, HSD17B13 provides an example of a protective genetic biomarker where the protein-truncating rs72613567 variant is associated with reduced chronic liver disease risk and lower progression from steatosis to steatohepatitis (35).”
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Zhu, G., Huang, Y., Huang, Y., & 杨文龙 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1962068
“In 2,391 human liver samples, it was associated with reduced risk of steatohepatitis but not of steatosis (37).”
InfluentialLi, C., Li, M., Wang, B., & Ji, G. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2737572
Navigating MASLD heterogeneity: from metabolic risk to precision stratification
Yan, C., Zhang, G., Liang, L., & He, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1966460
Li, R., Huang, X., Li, S., & Zhang, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1916728
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.